JP Morgan Maintains Overweight on Ascentage Pharma Group, Lowers Price Target to $33

Benzinga Newsdesk www.benzinga.com Negative 88.6%

Neg 88.6% Neu 0% Pos 0%

JP Morgan analyst Brian Cheng maintains Ascentage Pharma Group (NASDAQ:AAPG) with a Overweight and lowers the price target from $46 to $33.